- IDEX Corporation’s Board previously approved a regular quarterly cash dividend of US$0.73 per common share, paid on July 24, 2026 to shareholders of record on July 6, 2026, marking the company’s 127th consecutive regular quarterly cash dividend.
- This long-running dividend record, combined with stronger-than-expected Q1 2026 results and a raised full-year outlook, underscores IDEX’s emphasis on consistent shareholder returns supported by operational performance.
- We’ll now examine how IDEX’s better-than-expected Q1 results and higher full-year outlook reshape its existing investment narrative.
Find 45 companies with promising cash flow potential yet trading below their fair value.
IDEX Investment Narrative Recap
To own IDEX, you generally need to believe in its ability to convert specialized industrial and healthcare exposure into steady cash generation and disciplined capital returns. The latest dividend affirmation, coupled with strong Q1 2026 results and a higher full year outlook, supports that case but does not materially change the near term balance between the key catalyst of improving orders and the ongoing risk of policy and geopolitical uncertainty weighing on project demand.
The strongest recent announcement tied to this dividend news is IDEX’s better than expected Q1 2026 report, with higher sales and earnings versus the prior year and a raised outlook. Together, resilient earnings, a long dividend record and ongoing buybacks point to a business that is currently using its cash flows to reward shareholders even as it works through sector specific volume pressures in areas like chemicals, energy and certain end markets.
Yet even with the raised outlook, investors should be aware that tariff driven cost inflation could still...
Read the full narrative on IDEX (it's free!)
IDEX's narrative projects $4.2 billion revenue and $697.3 million earnings by 2029. This requires 5.6% yearly revenue growth and a $189.6 million earnings increase from $507.7 million today.
Uncover how IDEX's forecasts yield a $238.29 fair value, a 6% upside to its current price.
Exploring Other Perspectives
Three fair value estimates from the Simply Wall St Community span roughly US$180 to about US$264 per share, showing how far apart individual views can be. When you set those against IDEX’s focus on cost savings as a key earnings catalyst, it underlines why checking several different opinions before forming your own view on the company’s prospects can be helpful.
Explore 3 other fair value estimates on IDEX - why the stock might be worth as much as 18% more than the current price!
Form Your Own Verdict
Don't just follow the ticker - dig into the data and build a conviction that's truly your own.
- A great starting point for your IDEX research is our analysis highlighting 3 key rewards that could impact your investment decision.
- Our free IDEX research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate IDEX's overall financial health at a glance.
Contemplating Other Strategies?
Our top stock finds are flying under the radar-for now. Get in early:
- Uncover the next big thing with 24 elite penny stocks that balance risk and reward.
- AI is about to change healthcare. These 40 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
- We've uncovered the 8 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com